

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE
PUBLIC RECORDS

02 FEB 14 P

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Genentech, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 808 17th Street, NW Suite 250 City Washington State/Zip (or Country) DC 20006 USA			
3. Principal Place of Business (if different from line 2) City S. San Francisco State/Zip (or Country) CA 94080 USA			
4. Contact Name Walter Moore			5. Senate ID # 15920-12
7. Client Name <input type="checkbox"/> Self Self			6. House ID # 31464000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) ☐ OR Year End (July 1-Decen

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ >> Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ \$700,000.00 Expenses (nearest \$20,000) 14. REPORTING METHOD. Check box to indicate ex accounting method. See instructions for description of opt <input type="checkbox"/> Method A. Reporting amounts using LDA definition: <input type="checkbox"/> Method B. Reporting amounts under section 6033(b) the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code

Signature Walter Moore

Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2002,

H.R.698, Prescription Reimportation, Improvement, Correction, and Enhancement Act, Reimportation of Prescription Drugs

S. 1229, To amend the Federal Food, Drug, and Cosmetic Act to permit individuals to import prescription drug in limited circumstances. ,

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Moore, Walter	
Wagner, Heidi	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature Walter Moore Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**H.R.1862, Greater Access to Affordable Pharmaceuticals Act of 2001,
S.812, Greater Access to Affordable Pharmaceuticals Act of 2001,**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Moore, Walter	
Wagner, Heidi	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature Walter Moore

Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

**H.R. 3448, Public Health Security and Bioterrorism Response Act of 2001,
Issues Relating to Hosp Outpatient Payment System, ,
S. 1715/S.1765, Bioterrorism Preparedness Act of 2001,
S.318, Genetic Nondiscrimination in Health Insurance and Employment Act,
S.382, Genetic Information Nondiscrimination in Health Insurance Act of 2001,
Issues Relating to HHS Privacy Rule**

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

**Department of Health & Human Services
House of Representatives
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Moore, Walter	
Wagner, Heidi	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

S. 1135, Medicare Reform Act of 2001,

S. 1185, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 2001,

S.357, Medicare Preservation and Improvement Act of 2001,

S.358, Medicare Prescription Drug and Modernization Act of 2001,

HHS issues relating to Medicare Reimbursement

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

Department of Health & Human Services

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Moore, Walter	
Wagner, Heidi	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code SCI (one per page)

16. Specific Lobbying issues
No specific legislation

17. House(s) of Congress and Federal agencies contacted

☒ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Moore, Walter	
Wagner, Heidi	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature

Walter Moore

Date 2/14/02

[REDACTED]

Registrant Name: Genentech, Inc.

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues
S1940, Ending the Double Standard for Stock Options Act,
~~No specific legislation~~

17. House(s) of Congress and Federal agencies contacted
Senate

☐ Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Moore, Walter</u>	
<u>Wagner, Heidi</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature



Date 2/14/02

[REDACTED]

Registrant Name: **Genentech, Inc.**

Client Name: **Self**

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

GOV, MAN

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Own in
Roche Holding Ltd	c/o F. Hoffmann La Roche AG Basel CH-1002 Switzerland		\$0.00	58

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, or affiliated organization

Signature



Date **2/14/02**

[REDACTED]